Clinical Trials Logo

Filter by:
NCT ID: NCT04922658 Recruiting - Clinical trials for Advanced Non-Small Cell Lung Cancer

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC

NCT ID: NCT04922567 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)

NCT ID: NCT04922541 Recruiting - Clinical trials for Plaque, Atherosclerotic

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Start date: November 1, 2019
Phase:
Study type: Observational

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

NCT ID: NCT04922450 Recruiting - Clinical trials for Head and Neck Cancer

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.

NCT ID: NCT04922151 Recruiting - Clinical trials for Pathological Myopic Choroidal Neovascularization

601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

NCT ID: NCT04922138 Recruiting - Lung Cancer Clinical Trials

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

APPOINT
Start date: January 14, 2022
Phase: Phase 2
Study type: Interventional

Efficacy and safety of postoperative adjuvant treatment of NSCLC patients with Aumolertinib.

NCT ID: NCT04922047 Recruiting - Clinical trials for Urinary Bladder Neoplasms

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

TACBIN-01
Start date: June 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, single-center study to assess the safety of tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have been diagnosed with high-risk NMIBC without prior BCG treatment.

NCT ID: NCT04921995 Recruiting - Chemotherapy Effect Clinical Trials

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma

RETICULA-NPC
Start date: April 15, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent loco-regionally advanced nasopharyngeal carcinoma. Patients who did not respond to or progressed on another ICI are allowed to receive tislelizumab rechallenge as a subgroup.

NCT ID: NCT04921722 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

Start date: October 22, 2021
Phase: Phase 4
Study type: Interventional

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

NCT ID: NCT04921527 Recruiting - Ovarian Cancer Clinical Trials

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

CHIPRO
Start date: December 20, 2021
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.